

5th February, 2026

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Dear Sir / Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') – Completion of tenure of Independent Director

Pursuant to Regulation 30 of the SEBI Listing Regulations, the Company hereby informs that Mr. Subramanian Ramadorai (DIN: 00000002) completes his term of 5 (five) consecutive years as Independent Director of the Company, on February 8, 2026. Mr. Ramadorai has expressed his desire to retire from the Board in the interest of pursuing personal priorities and has therefore not offered himself up for appointment for a second term.

Accordingly, Mr. Ramadorai ceases to be an Independent Director of the Company with effect from 9th February, 2026 and consequently, as Chairman/Member of the various Board Committees on which he served. The Board has re-constituted the Committees in accordance with applicable regulatory requirements.

The Board places on record its heartfelt gratitude for the valuable insights and guidance received from Mr. Ramadorai during his tenure on the Board. There is no material reason for his cessation other than as mentioned above.

Kindly take this on record and oblige.

Thanking you,

Sincerely,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary